Join to View Full Profile
20 York StNew Haven, CT 06510
Phone+1 203-688-4242
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kurt Schalper, MD is a pathologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut.
Certifications & Licensure
CT State Medical License 2017 - Present
Publications & Presentations
PubMed
- The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.Shruti S Desai, Syim Salahuddin, Ramsey Yusuf, Kishu Ranjan, Jianlei Gu
The Journal of Clinical Investigation. 2025-07-15 - Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl
Journal of Thoracic Oncology. 2025-07-07 - A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.Jonathan W Riess, Matthew S Lara, Guillaume Luxardi, Miguel Lopez de Rodas, Michiko Shimoda
JTO Clinical and Research Reports. 2025-06-01
Press Mentions
AACR Annual Meeting 2025 Plenaries: Cancer Evolution, Tumor Microenvironment, Drugging KRAS, and MoreMay 29th, 2025- Navigating the Meandering Path of Oncology Drug DevelopmentMay 28th, 2025
- Daily Takeaways from the AACR Annual Meeting 2025: Tuesday, April 29April 29th, 2025
- Join now to see all
Grant Support
- Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancerYALE UNIVERSITY2021–2026
- Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancerYALE UNIVERSITY2021–2026
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersEMORY UNIVERSITY2018–2024
